2006-2007 CGR
2006-2007
Cardiovascular Medicine Grand Rounds
“Nitric Oxide Regulation of Exocytosis
and Vascular Inflammation”
Charles J. Lowenstein, M.D.
Professor, Department of Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland
determine how nitric oxide inhibits vascular inflammation
[two_half]Sept. 5, 2006[/one_half]
No CGR
“The Value and Interpretation of
Elevated Troponin Levels”
Allan S. Jaffe, M.D.
Professor of Medicine
Cardiovascular Diseases and
Laboratory Medicine and Pathology
Mayo Clinic College of Medicine
Rochester, Minnesota
understand the use of present day troponin assays
determine the importance of rising troponin values today and for the future
evaluate elevations of troponin not due to overt coronary artery disease.[/three_half_last]
“Cardiovascular Interventional
Magnetic Resonance Imaging (MRI)”
Robert Lederman, M.D.
Primary Investigator, Cardiology Branch
National Heart, Lung, and Blood Institute
Bethesda, Maryland
discuss the benefits of cardiovascular interventional MRI
recall the techniques of cardiovascular interventional MRI
The Crampton Lecture
“Stem Cells for Cardiac Regeneration”
Eduardo Marban, M.D., Ph.D.
Chief of Cardiology
Professor of Medicine,
Physiology and Biomedical Engineering
Michel Mirowski, M.D. Professor of Cardiology
Director, Donald W. Reynolds Cardiovascular
Clinical Research Center
Editor-in-chief, Circulation Research
Director, Institute of Molecular Cardiobiology,
The Johns Hopkins University
Baltimore, Maryland
to understand the objectives of regenerative therapy for heart disease
to understand the scientific basis for stem cell therapy and its limitations
“Lessons from Registries:
The Real World vs Optimal Acute Coronary
Syndrome (ACS) Patient Management”
Peter B. Berger, M.D.
Associate Chief Research Officer for Clinical Research
Geisinger Health System
Danville, Pennsylvania
describe the epidemiology and pathophysiology of acute coronary syndrome
explain key updates to the ACC/AHA guidelines for UA/NSTEMI and STEMI
interpret findings from ACS registries as the relate to patient management in current clinical practice
utilize critical pathways to apply evidence-based medicine in clinical practice
“Vascular Smooth Muscle Phenotypic
Modulation: Atherosclerosis,
Sphingosine-1-phosphate and Ion Channels”
Brian Wamhoff, Ph.D.
Assistant Professor
Internal Medicine, Cardiovascular Division
University of Virginia Health System
Charlottesville, Virginia
The utility of transgenic and Cre/lox mouse models to study smooth muscle phenotypic modulation in vascular disease.
To understand the role of the bioactive phospholipid sphingosine-1-phosphate in smooth muscle phenotypic modulation in vitro and in vivo.
To understand the role of ion channels in regulating smooth muscle cell phenotype in vitro and in vivo.
“Understanding the Complexities
of High Density Lipoproteins”
Thomas Dayspring, M.D.
Clinical Assistant Professor of Medicine
University of Medicine and Dentistry of New Jersey
New Jersey Medical School, Newark, NJ
Director, North Jersey Institute of
Menopausal Lipidology
Wayne, NJ
understand current classification and complexities of HDL particles
recognize the functionality of HDL particles and their role in peripheral cholesterol transport and vascular health.
determine how HDL particles can be modified therapeutically
“Reperfusion Strategies in Patients with
ST-Elevation Myocardial Infarction (STEMI)”
Eric Bates, M.D.
University of Michigan
Summarize ACC/AHA recommendations for choosing fibrinolysis or PCI in managing patients with STEMI
Outline pharmacologic and mechanical reperfusion strategies, including fibrinolytic dosing, timing of reperfusion, and transfer protocols for hospitals with and without catheterization labs
Describe key findings from trials that support current ACC/AHA guidelines for STEMI
Develop critical pathways for managing patients with STEMI based on ACC/AHA guidelines
“Optimizing Outcomes in Patients
with Multiple Cardiovascular Risks”
Robert Vogel, M.D.
Professor of Medicine
Director, Clinical Vascular Biology
Maryland Heart Center
University of Maryland Medical Center
Baltimore, Maryland
understand the relationship between multiple risk factors in the progression of cardiovascular disease.
examine pathophysiologic mechanisms of concomitant cardiovascular risk factors.
interpret key findings of recent clinical trials that support early, aggressive therapies for cardiovascular risk reduction.
Annual Conference
No CRG
Thursday
Jordan Hall Conference Center
“The Role of Atherosclerosis
Imaging in Risk Stratification and
Disease Progression in Asymptomatic
Diabetic Patients”
Avijit Lahiri, M.D.
The Wellington Hospital
London, England
recognize new imaging modalities in high risk risk asymptomatic population.
“ABCG1 and Reverse Cholesterol Transport
in Diabetic Atherosclerosis”
Catherine C. “Lynn” Hedrick, M.D.
Associate Professor of Medicine
Cardiology Division
Department of Internal Medicine
University of Virginia Health System
Charlottesville, Virginia
to learn about novel cholesterol transporters and their role in reverse cholesterol transport and HDL metabolism
to learn how reverse cholesterol transport is modified in diabetes and how this contributes to atherosclerosis
to learn about new 0therapeutic targets related to HDL metabolism that could be beneficial for reduction of atherosclerotic plaque progression in diabetes.
CANCELLED
“Management of Patients with
ST-Elevation Myocardial Infarction (STEMI)”
David Janicke, M.D.
Professor of Medicine
State University of New York
Buffalo, New York
Discuss updates to the ACC/AHA STEMI guidelines
Outline the key issues in timing and potential transfer for PCI in patients who are candidates for fibrinolysis
Describe key registries and quality improvement programs for improving the management of STEMI
“Management of Pulmonary Hypertension”
Amy L. Tucker, M.D.
Associate Professor of Medicine
Cardiology Division, Department of Internal Medicine
University of Virginia Health System
Charlottesville, Virginia
Understand the use of a mechanistic classification of pulmonary hypertension to guide diagnosis and treatment strategies.
Understand the pathophysiology of pulmonary hypertension and the three major pathways targeted with advanced therapies.
Know how to use prostanoids, endothelin receptor antagonists, and PDE inhibitors for treatment of severe pulmonary hypertension
“Vascular Smooth Muscle Cells
and Atherosclerosis: from
Sphingolipids to Ion Channels”
Brian Wamhoff, M.D.
Assistant Professor of Medicine
Cardiology Division, Department of Internal Medicine
University of Virginia Health System
Charlottesville, Virginia
should be able to:
demonstrate a fundamental understanding of vascular smooth muscle cell phenotypic modulation in vascular disease.
recognize sphingosine-1-phosphate as a novel mediator of smooth muscle cell phenotype.
recall the role of ion channels in regulating smooth muscle cell phenotype, AKA excitation-transcription coupling.
No CGR
No CGR
“A Novel Approach to Cardiometabolic Risk Reduction: Role of the Endocannabinoid System”
David Bell, M.B.
Professor of Medicine,
University of Alabama School of Medicine
Birmingham, Alabama
assess patients for cardiovascular and metabolic risk factors.
demonstrate the relationship between intra-abdominal adiposity and cardiovascular and metabolic risk in overweight patients.
describe the mechanism of action of the endocannabinoid system in regulating glucose and lipid metabolism.
examine the potential role of CB1 receptor blockers in modifying cardiovascular and metabolic risk and preventing the progression to cardiovascular and metabolic diseases.
“Vascular Inflammation and Immunity
in Atherosclerosi”
Klaus Ley, M.D.
Director of the Cardiovascular Research Center
and Professor of Biomedical Engineering
University of Virginia Health System
Charlottesville, Virginia
recall the current concepts in monocyte recruitment, retention and differentiation in the arterial wall.
recognize the role of T, B, and natural killer T lymphocytes in atherosclerosis
“Drug Eluting Stents”
David R. Holmes, M.D.
Professor of Medicine
Cardiology Division,
Department of Internal Medicine
Mayo Clinic School of Medicine
Rochester, Minnesota
evaulate stent thrombosis – frequency, timing, prevention, and new approaches
“Looking at New Treatments for
Ischemia and Angina”
Peter Stone, M.D.
Brigham and Women’s Hospital
Boston, Massachusetts
” Perspectives on Device Technology:
Problems and Solutions”
Kenneth Alan Ellenbogen, M.D.
Professor of Medicine
Virginia Commonwealth University
Medical College of Virginia
Richmond, Virginia
conduct an assessment of ICD malfunction
recognize the presentation and frequency of ICD lead malfunction development of algorithms
predict lead failure development of leadless ICD/ pacing management of device failure decision analysis model of patient management
Cancelled
due to weather
“Treatment of Advanced Heart Failure”
Leslie Miller, M.D.
Director of Cardiology
Washington Hospital Center and
Georgetown University Hospital
Walters Chair of Cardiology
Georgetown University School of Medicine
determine the prognosis for patients with advanced heart failure and the risk factors that influence outcome.
identify the treatment options for advanced heart failure.
recognize the criteria used to guide patient selection for the various treatment options.
recall the clinical variables such as recurrent admissions that should prompt a referral to a center for advanced heart failure.
“A Trip Down Memory Lane: Almost 2 Decades
in The Cardiovascular Division at UVA…”
Ian J. Sarembock, M.D., Ch.B., M.B.
Professor of Internal Medicine
Director of the Coronary Care Unit
University of Virginia
provide insights into the practice of clinical cardiology
provide insights into collaborative and translational research
outline educational and mentoring initiatives
“Recent Progress in Invasive and Noninvasive
Molecular Imaging of Vulnerable
Atherosclerotic Plaques”
George Beller, M.D.
Ruth C. Heede Professor of Cardiology
Professor of Internal Medicine
Director, Enhanced External Counterpulsation Program
recall up-to-date information on the feasibility of detecting components of vulnerable plaques by noninvasive imaging using ultrasound, nuclear techniques, CT and MRI.
recognize that molecular imaging of atherosclerotic plaques may be clinically useful in identifying high risk patients prone to developing an ACS.
demonstrate that medical therapy can be monitored using targeted molecular imaging techniques
“Update on Antithrombotic Therapy for PCI
and Acute Coronary Syndromes.”
Michael Cowley, M.D.
Professor of Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, VA
discuss newer clinical trial results on antithrombotic therapy for acute MI, acute coronary syndromes, and coronary intervention.
“The Genetic Basis of
Subclinical Cardiovascular Disease”
Stephen S. Rich, M.D.
Director of the Center for Public Health Genomics
University of Virginia
Charlottesville, Virginia
identify the approaches for deciding whether genetic factors contribute to risk of cardiovascular disease
using subclinical measures of cardiovascular disease, recall the evidence that genetic factors determine variation in those measures
recognize current approaches to identifying genes that modify risk of cardiovascular disease
provide an evaluation of the proposed cardiovascular risk factor genes
“Treatment of Atrial Fibrillation in Patients with Heart Failure: When Is Rhythm Control Worthwhile?”
John D. Ferguson, M.D.
Assistant Professor of Medicine
Cardiology Division, Department of Internal Medicine
University of Virginia Health System
Charlottesville, Virginia
discuss the impact of AF on heart failure.
explain the role of anti-arrhythmic drugs, AV junction ablation and catheter ablation.
demonstrate examples of effective treatment.
Annual Conference
NO CRG
“Treatment of Advanced Heart Failure”
Leslie Miller, M.D.
Chief of the Intergrated Divisions of Cardiology:
WHC, MedStar GUH, GUMC;
Walters Chair
Georgetown University Hospital
Washington, DC
recognize the prognosis for patients with advanced heart failure and the risk factors that influence outcome.
recall the treatment options for advanced heart failure.
recognize the criteria used to guide patient selection for the various treatment options.
recognize the clinical variables, such as recurrent admissions, that should prompt a referral to a center for advanced heart failure.
“Role of the Angiotensin AT2 Receptor in
Cardiovascular and Renal Function”
Robert Carey, M.D.
David A. Harrison, III Distinguished Professor of Medicine
University Professor and Dean, Emeritus
Professor of Medicine
University of Virginia School of Medicine
recognize the tissue expression and actions of AT1 and AT2 receptors
recall the scientific approaches to discovery of receptor function
determine and evaluate the use of angiotensin receptor blocker therapy in cardiovascular disease.
“The Importance of Time
to Reperfusion in ST Elevation MI”
Lawrence Gimple, M.D.
Professor of Medicine
Director of Clinical Cardiology
University of Virginia
determine how door to balloon time fits into a Quality Improvement Program.
recognize the clinical evidence for PCI for acute myocardial infarction.
recall the limitations of door to balloon time in a “real world setting”.
The 24th Annual
Marjorie and Jaye Grollman Lecture
Medical Grand Rounds
Monday
Camp Heart Auditorium
“Should All Patients with Low
Ejection Fraction Get ICD’s?”
Mark E. Josephson, M.D.
Herman Dana Professor of Medicine
Director, Clinical Cardiac Electrophysiology:
BIDMC Program
Beth Israel Deaconess Medical Center
and Harvard Medical School
Boston, Massachusetts
Cardiology Grand Rounds
Tuesday
Camp Heart Auditorium
“AF Ablation: Rationale and Techniques?”
Mark E. Josephson, M.D.
Herman Dana Professor of Medicine
Director, Clinical Cardiac Electrophysiology:
BIDMC Program
Beth Israel Deaconess Medical Center
and Harvard Medical School
Boston, Massachusetts
“Percutaneous Heart Valve Therapy”
Michael J. Mack, M.D.
Cor Specialty Associates of North Texas
Dallas, Texas
describe current field of percutaneous treatment of valvular heart disease
define patient populations for percutaneous valve treatments
discuss the impact on surgical therapy
“What’s Blood Got to Do with It? Anemia as a Therapeutic Target in Heart Failure”
G. Michael Felker, M.D.
Duke University School of Medicine
Cardiovascular Division
Durham, NC
differentiate observational data suggesting that anemia is common and a marker of adverse prognosis in patients with heart failure
recognize the theoretical risks and benefits of targeting anemia in patients with heart failure
CANCELLED
“Percutaneous Treatment of
Valvular Heart Disease”
Fadi El-Ahdab, M.D.
Cardiology Fellow
University of Virginia Health System
Charlottesville, Virginia
recognize the available techniques for treatment of valvular heart disease,
recall the indications and the efficacy of percutaneous therapies for valvular heart disease,
recognize the new techniques for treating valvular heart disease.
“TBA”
Name, M.D.
Professor of Medicine
No CGR
“Future Therapy for Acute Myocardial Infarction: Attenuation of Reperfusion Injury
with Adenosine A2A Receptor Agonists”
Rajan Patel, M.D.
Chief Fellow – Cardiology
University of Virginia Health System
Charlottesville, Virginia
recognize the clinical consequences of reperfusion injury after acute myocardial infarction
recall the cellular pathophysiology of reperfusion injury after acute myocardial infarction
identify the potenial mechanism and role of the adenosine A2A receptor agonist ATL146e in attenuating reperfusion injury after acute myocardial infarction
“Identifying Athletes at Risk for Sudden
Cardiac Arrest: Balancing Cost and Risk”
Jason West, M.D.
Cardiology Fellow
University of Virginia Health System
Charlottesville, Virginia
describe AHA and ESC Preparticipation Sports Screening Guidelines
identify modalities for the detection of LVH
“Hypertensive Diseases of Pregnancy
and Future Cardiovascular Risk.”
Carolyn Z. Behm, M.D.
Cardiology Fellow
University of Virginia Health System
Charlottesville, Virginia
identify the risk factors for the hypertensive diseases of pregnancy
recall factors for the diagnosis of the hypertensive diseases of pregnancy
recognize the future cardiovascular risk of women with hypertensive diseases during pregnancy